Amgen has enrolled over 3,500 patients in its MARITIME Phase 3 program, with readouts expected in early 2027
As part of the evolving R&D pipeline, Figure 3 summarises the emerging research frontiers into the potential therapeutic applications of GLP-1s beyond cardiometabolic conditions, including neurodegeneration, addiction, mental health, cancer, womens health and asthma
No significant effect on ACTH stimulation
Understanding the control of hypercholesterolemia and dyslipidemia beginning in midlife, when its detrimental effects to brain health are thought to be most pervasive (Anstey et al., 2017), may provide new insights into the potential use of statins and or the identification of novel targets that could advance midlife preventive strategies for dementia in certain populations
Dual GIP/GLP-1 receptor co-agonists The discovery of the first GIP/GLP-1 receptor co-agonist was reported in 2013 [74]